Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases...

Full description

Bibliographic Details
Published in:Frontiers in Immunology
Main Authors: Karin Teppert, Nora Winter, Vera Herbel, Caroline Brandes, Simon Lennartz, Fabian Engert, Andrew Kaiser, Thomas Schaser, Dominik Lock
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Subjects:
immunotherapy
adoptive T cell therapy
chimeric antigen receptor
chimeric costimulatory receptor
melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1178060/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1178060/full

Similar Items